ArticleFrontiers in oncology2024

PXDN as a pan-cancer biomarker and promotes tumor progress via immune inhibition in nasopharyngeal carcinoma.

Yu-Chun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.